The genetic channelopathies are a broad collection of diseases. Many ion channel genes demonstrate wide phenotypic pleiotropy, but nonetheless concerted efforts have been made to characterise genotypephenotype relationships. In this review we give an overview of the factors that influence genotypephenotype relationships across this group of diseases as a whole, using specific individual channelopathies as examples. We suggest reasons for the limitations observed in these relationships. We discuss the role of ion channel variation in polygenic disease and highlight research that has contributed to unravelling the complex aetiological nature of these conditions. We focus specifically on the quest for modifying genes in inherited channelopathies, using the voltage-gated sodium channels as an example. Epilepsy related to genetic channelopathy is one area in which precision medicine is showing promise. We will discuss the successes and limitations of precision medicine in these conditions. This article is part of the Special Issue entitled 'Channelopathies.' Crown
Introduction
Ion channels are a broad category of transmembrane proteins that share the physiological property of being involved in the regulation of ion flux across cell membranes. In the human genome there are over 400 genes encoding ion channels. Ion channels are expressed in almost all cell membranes, as well as in the membranes of many intracellular organelles, and they are involved in a diverse range of physiological processes. It is therefore no surprise that ion channel dysfunction has been implicated in a wide spectrum of human diseases. The clinical features and age of presentation of diseases related to ion channel dysfunction are dependent on the physiological role of the ion channel in question, as well as the tissue-specific and age-specific expression of its gene(s). Many different mechanisms may lead to ion channel dysfunction, including primary genetic defects in the coding sequence for the channel protein itself, genetic defects in genes and/or noncoding DNA implicated in the expression and regulation of ion channel genes, and acquired ion channel dysfunction as a result of autoimmune destruction of ion channels, which itself is likely to have genetic determinants. Acquired ion channel dysfunction has been observed in rats with chemically-induced seizures, and is likely to involve a mixture of direct toxic/ischaemic damage to ion channels, epigenetic dysregulation of ion channel genes, and intrinsic susceptibility to ion channel dysfunction. In turn, intrinsic susceptibility to ion channel dysfunction is likely to be determined by genetic variants in the ion channel itself, variants in genes that are involved in regulating ion channel genes, and the immune system. Thus, in the channelopathies, as with most human disease, a picture emerges of a complex interplay between genetic, epigenetic, and environmental factors. The case that such complex interplay is likely to underlie all the channelopathies, even those with apparently "monogenetic" causes, is evidenced by the finding that clear genotype-phenotype relationships are rarely observed in these conditions. (see Fig. 1) 
Genetic channelopathies
Since ion channels are present in almost all tissues, and they perform a wide range of functions, ion channel disease presents a highly diverse group of conditions. Fig. 1 summarises the currently known human channelopathies. Complete details and references are available in the data supplement.
Phenotypic pleiotropy
A brief glance at Fig. 1 will immediately reveal that pathogenic variants in many ion channel genes are associated with remarkable phenotypic pleiotropy. For example, heterozygous mutations in the potassium channel gene KCNQ2 have been identified in three distinct neurological disorders: self-limiting familial neonatal seizures , early infantile developmental and epileptic encephalopathy (Weckhuysen et al., 2012) , and peripheral nerve hyperexcitability (Wuttke et al., 2007) . In some cases phenotypic pleiotropy extends beyond a single organ system: KCNJ5 mutations have been found in long-QT syndrome , Andersen Tawil Syndrome (a multisystem disorder characterized by periodic paralysis, ventricular arrhythmias, and distinctive dysmorphic facial and/or skeletal features) (Kokunai et al., 2014) , and in familial hyperaldosteronism (Choi et al., 2011) . In fact, phenotypic pleiotropy is more the rule than the exception in the genetic channelopathies. Now that the extent of phenotype variability associated with ion-channel genes has been widely appreciated, recent scientific efforts have focussed gaining a deeper understanding of how any particular mutation may relate to the phenotype seen: the so-called "genotype-phenotype relationship."
Factors influencing the genotype-phenotype relationship

Mutation hotspots
In all known ion channel diseases in which non-truncating variants have been implicated, mutational hotspots, regions of the gene where there is clustering of pathogenic variants in association with disease, are seen. These hotspots correspond with functionally important regions of the ion channel, such as the voltage-sensor region, ligand binding site, or the pore-forming region (Zuberi et al., 2011 ). These regions demonstrate low mutational tolerance across species and within healthy human populations (Swanger et al., 2016) . In those channelopathies in which a spectrum of disease severity is observed, there is a sense that in more severe cases, mutations are more likely to be observed in functionally important regions, though even in one of the most well studied channelopathy genes, SCN1A, this remains to be proven (Harkin et al., 2007) .
Single variant correlations
In a minority of channelopathies certain phenotypes have only ever been observed in association with a single variant, or amino acid change. An example of this is CAPOS (Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy, and Sensorineural deafness) syndrome, which is caused by heterozygous mutations in the ATP1A3 gene, encoding the catalytic a 3 subunit of the Na
Heterozygous missense mutations in ATP1A3 have been observed in two other phenotypes: alternating hemiplegia of childhood (AHC) (Rosewich et al., 2012) , and rapid onset parkinsonism dystonia (RPD) (de Carvalho Aguiar et al., 2004) . In AHC and RPD, causative mutations have been identified across the length of the gene, though only one variant (p. Asp923Asn) has been found in both AHC and RPD patients (Zanotti-Fregonara et al., 2008; Anselm et al., 2009; Roubergue et al., 2013) . However, in CAPOS syndrome, only a single, recurrent, causative variant (p.Glu818Lys) has been identified (Demos et al., 2014; Heimer et al., 2015; Potic et al., 2015) . It has been postulated that the reason that the p.Glu818Lys mutation leads to a the distinct phenotype of CAPOS syndrome is because this mutation would be predicted to lead to a gain-of-function in the ion channel (Demos et al., 2014) , whereas the disease-causing mutations seen in AHC and RPD cause a loss-of-function) (de Carvalho Aguiar et al., 2004) . However, no formal functional studies have been published using a p.Glu818Lys model to back up this theory. With mutations in the potassium channel gene KCNQ2, the phenotype seen is of focal tonic seizures beginning in the first days of life. Recently, the single variant (p.Arg198Glyn) has been found in five cases who did not have neonatal seizures, but presented with infantile spasms, hypsarrhythmic EEG, and marked developmental regression between 4 and 6 months of life. Using in vitro electrophysiology studies, the authors demonstrated that this variant conferred gain-of-function properties on the ion channel (Millichap et al., 2017) . In SCN2A, a gene in which mutations are associated with a wide variety of epilepsy phenotypes, the recurrent p.Arg853Gln variant has been found exclusively in cases presenting with infantile spasms (Wolff et al., 2017) .
Predicted pathogenicity of variants
A number of commercially available in silico tools (SIFT ® , Polyphen ® , Mutation Taster ® ) are frequently used to help geneticists predict the likely pathogenicity of genetic variant that has been identified through sequencing. These tools typically incorporate information about the evolutional conservation of the affected sequence as well as observed mutation rates in healthy populations. Often, in clinical practice, such tools are used in a rather binary fashion to determine whether a genetic variant is causative or not. However, in reality there is likely to be a spectrum of pathogenicity observed with many rare variants. In time, if large shared datasets are collected systematically, in silico tools may be used to help define the spectrum of many channelopathies.
The best example of a channelopathy in which the pathogenicity scores have been shown to correlate with phenotype is epilepsy due to SCN1A mutations. To date more than 1200 different mutations in the SCN1A gene have been identified in association with epilepsy (Dj emi e et al., 2016) . Milder cases of SCN1A-related epilepsy are often inherited and cause familial febrile seizures, and genetic epilepsy with febrile seizures plus (GEFSþ) (Claes et al., 2001) , whereas at the opposite end of the phenotypic spectrum is Dravet syndrome, a severe epilepsy beginning in infancy, in which developmental stagnation is often seen with epilepsy onset (Escayg et al., 2000b) . Zuberi et al. demonstrated that where SCN1A mutations affected the voltage sensing region of the channel, patients with Dravet syndrome had significantly greater silico evidence of pathogenicity than patients with GEFSþ (Zuberi et al., 2011) .
Functional effects of mutations
Defining the functional effects of a genetic variant is gold standard for proving pathogenicity, and requires in vitro and/or in vivo modelling. The most commonly used models involve transfecting cell lines (for example human embryonic kidney cells or Xenopus laevis oocytes) with the variant being investigated, and then using the patch clamp technique (Neher and Sakmann, 1976) to measure the properties of ion currents compared with wild-type cells (Shalaby et al., 1997) .
Based on such functional characterisations, ion channel mutations are often referred to as either "loss-of-function" or "gain-offunction," though in reality such terms oversimplify what are often complex alterations in ion channel function (Swanger et al., 2016) . Broadly speaking, loss-of-function mutations are associated with reduced channel permeability, and gain-of-function mutations lead to an increase in ion flux.
Loss-of-function
On the whole, disease causing missense mutations in ion channel genes are more likely to result in reduced permeability (loss-of-function) than increased permeability (gain-of-function). Reduced ion permeability may also result from a whole gene deletion or truncation mutation as a result of halpoinsufficiency. For some ion channels, such as Na v 1.1 and K v 7.2 (Schroeder et al., 1998) normal ion channel function appears to be dependant on biallelic expression of the gene, whilst other ion channels, such as CFTR, entirely tolerate haploinsufficiency without apparent functional consequence. Therefore, in the absence of functional studies, lossofion channel function cannot be inferred from the finding of a nonsense mutation, frameshift mutation, or whole gene deletion (null mutation). Furthermore, even in ion channels that do not tolerate haploinsuffiency, the functional consequences of null mutations may differ from those of loss-of function missense mutations. Compared with null mutations, loss-of-function missense mutations may either result in a functionally less impacted channel, due to residual function of the mutant channel, or conversely in a more severely affected channel, where there is a dominantnegative impact from the mutant on the wildtype channel (Shalaby et al., 1997; Warner et al., 2016) . A good example of how loss-of-function can take several different forms, and how this can influence phenotype, is seen with CHRND, which encodes the d polypeptide subunit of the nicotinic acetylcholine receptor expressed in skeletal muscle. Gain-of-function mutations in CHRND cause slow channel congenital myaesthenic syndrome (Gomez et al., 2002) , whilst loss-of-function of this channel can take three forms, with each associated with a different phenotype: recessive missense mutations that result in a slowing of channel opening cause fast channel congenital myasthenic syndrome (Gomez et al., 2002) ; recessive missense mutations that impair co-clustering of the acetylcholine receptor with rapsyn lead to reduced expression of normally functioning receptors, and have been found in association with a more severe congenital myasthenic syndrome (Müller et al. 2006) ; and recessive truncation mutations (i.e. complete deficiency) cause the most severe phenotype of multiple pterygium syndrome, an embryonically lethal syndrome associated with multiple bone and spinal fusions (Michalk et al., 2009 ). For some channelopathies distinct phenotypes are seen in the haploinssufficient state compared with the complete deficiency state (as a result of biallelic loss-of-function mutations). With SCN4A, heterozygous loss-of-function mutations lead to hypokalaemic periodic paralysis, hyperkalamic periodic paralysis or paramyotonia congenita (Pt a cek et al., 1991 (Pt a cek et al., , 1992 Jurkat-Rott et al., 2000; Pt a cek et al., 1992) , whilst biallelic loss-of-function mutations are associated with a distinct phenotype of congenital myasthenic syndrome (Tsujino et al., 2003) .
Gain-of-function
Even more than loss-of-function mutations, gain-of-function changes are currently very difficult to impute or model in silico, and almost always require in vitro techniques such as patch clamp to demonstrate. "Gain-of-function" refers to a variety of possible functional changes. Channels may be rendered in a permanently open state, or there may be an increased frequency of channel opening, and increased sensitivity to ligand binding, or delayed channel closure. These different gain-of-function effects demand different techniques to demonstrate. It has been shown in epilepsy related to gain-of-function KCNT1 and KCNQ2 variants, that the degree of increased channel permeability correlates with the severity of the phenotype (Millichap et al., 2017; Milligan et al., 2014) . To infer GOF in human tissue on the basis of single cell line functional models is problematic. The extent to which mutant channel subunits are expressed relevant in human brain tissue may not be known, and reduced cell surface expression of apparently functionally enhanced subunits, as a result of impaired trafficking (Swanger et al., 2016) may counteract any gain of function properties (Martin et al., 2010) . Demonstration of a gain-of-function mutation can have important therapeutic implications, since it is currently easier to block ion channels with medications than to open dysfunctional ones. This will be discussed in the precision medicine section of this paper.
Channelopathies with opposing phenotypes
There are some genetic channelopathies that demonstrate marked differences in the phenotypes observed with loss-offunction mutations versus gain-of-function mutations. The best examples of this are the congenital disorders of pain related to sodium channel mutations, and some of the potassium channelrelated cardiac dysrhythmias.
The sodium channel gene SCN9A encodes Na v 1.7, which is expressed predominantly in dorsal root ganglion cells and sympathetic ganglion neurons (Toledo-Aral et al., 1997) . Gain-offunction mutations in SCN9A have been found in two conditions characterized by excessive pain perception, primary erythromelagia and paroxysmal extreme pain disorder (Fischer and Waxman, 2010) whilst biallelic loss-of-function mutations in the same gene have been found in what could be considered an opposing phenotype, congenital insensitivity to pain (Cox et al., 2006) . A similar picture is seen in the cardiac channelopathies caused by KCNH2 and KCNQ1 where gain-of-function mutations are found in short QT syndrome (Brugada et al., 2004; Bellocq et al., 2004) , whilst loss-of-function mutations are seen in long QT syndrome (Curran et al., 1995; Wang et al., 1996) . These could also be considered opposing phenotypes, although both predispose to cardiac arrhythmias.
Complex genotype-phenotype relationships
Stark contrasts between the phenotypes associated with gainof-function and loss-of-function in ion channelopathies are in fact quite rare. More commonly a complex relationship between genotype and phenotype is observed. This is particularly the case with conditions that are known to have complex genetic aetiologies, such as epilepsy and the predisposition to cardiac dysrhythmia, where other genetic modifiers are likely to complicate the relationship between genotype and phenotype. These will be discussed in the section on the quest for modifying genes. Gain-of-function and loss-of-function mutations of KCNA2 have both been associated with a severe early-onset epilepsy phenotype, though efforts have been made to delineate the two phenotypes, which may become clearer with the discovery of more cases . Similarly, both gain-and loss-of-function variants have been found in severe early onset epilepsies caused by KCNB1(Torkamani et al., 2014), KCNQ2 (Weckhuysen et al., 2012; Millichap et al., 2017) , GRIN2A (Carvill et al., 2013) , GRIN2B (Lemke et al., 2014) , HCN1 (Nava et al., 2014) , and SCN2A (Wolff et al., 2017) , as well as in GEFS þ caused by SCN1A mutations (Lossin et al., 2002) . These findings suggest that in a state of health neuronal networks expressing these ion channels are poised in a state of equilibrium, the disruption of which, in either direction, can lead to excessive synchronous excitation (Swanger et al., 2016) . One of the reasons why disruption of this equilibrium in either direction can predispose to seizures is likely because most of these channels are expressed in both excitatory and inhibitory neurones. This is important to bear in mind when using drugs that act on ion channels to treat epilepsy since some drug classes when used in patients with particular channelopathies may lead to a paradoxical exacerbation of seizures, as is seen with the use of sodium-channelblocking drugs in SCN1A-related epilepsies (Brunklaus et al., 2013; Ogiwara et al., 2007) .
In some channelopathy-related epilepsies, a clear genotypephenotype relationship is seen at one end of the mutational spectrum, but the relationship becomes less clear beyond that. For example in SCN1A-related epilepsy a severe phenotype is typically seen with whole gene deletions and truncating mutations compared with missense mutations (Zuberi et al., 2011) , whilst in KCNQ2-related epilepsies the opposite is true, and whole gene deletions and truncation mutations are associated with selflimiting seizures Biervert et al., 1998; Allen et al., 2014; Claes et al., 2004; Miceli et al., 2013; Heron et al., 2007a,b) , whilst more severe epilepsies are always associated with missense mutations, presumably due to gain-of-function, or dominant negative effects (Weckhuysen et al., 2012; Millichap et al., 2017; Miceli et al., 2013; Saitsu et al., 2012; Borgatti et al., 2004) .
Such is the complexity of genotype-phenotype relationships in the channelopathies, and the myriad of variables that could potentially influence this, progress in this area will undoubtedly depend on large international data-sharing efforts in which extensive phenotype and genotype data are shared in common databases, as exemplified by the Epilepsy Phenome/Genome project (http://www.epgp.org).
Ion channel-regulating genes
The genetic channelopathies are not restricted purely to conditions caused by mutations in genes encoding the ion channels themselves. Many other genes are likely to play roles in the regulation of ion channels at molecular (e.g. accessory subunits), transcriptional (e.g. chromatin regulating genes), and translational (e.g. microRNA) (Jiang et al., 2012; Wang, 2013) levels. Genes encoding ion channel accessory subunits are included in red in the data supplement. Pathogenic mutations in CNTN2 (Stogmann et al., 2013) and CNTNAP2 (Strauss et al., 2006) , which encode contactin associated protein 2 (CASPR2) have been shown to disrupt clustering of potassium channels at the nodes of Ranvier in myelinated axons (Poliak et al., 2003; Peñagarikano et al., 2012) and cause a childhood-onset epilepsy with associated regression in speech development (Smogavec et al., 2016) . FGF12 and FGF13 encode fibroblast growth factor proteins which interact with the C-terminus of voltage gated sodium channels (Goldfarb, 2012) , and mutations in these genes have been found in patients with similar phenotypes to those seen in SCN1A-related epilepsy (Puranam et al., 2015; Siekierska et al., 2016; Al-Mehmadi et al., 2016) . In cardiology, a large number of genes (Shy et al., 2013) , including SNTA1 (Wu et al., 2008 ), MOG1 (Kattygnarath et al., 2011 ), and GP1DL (Van Norstrand et al., 2007 have been shown to interact with Na v 1.5, and have been implicated in causing Brugada and long-QT syndromes. In neuromuscular disease, rapsyn, encoded by the RAPSN gene, is known to play a major role in the localisation of skeletal muscle acetylcholine receptors (Apel et al., 1995) , and RAPSN mutations are associated with congenital myaesthenic syndrome (Ohno et al., 2002) and fatal akinesia deformation sequence (Michalk et al., 2009 ).
The role of ion channels in complex genetic diseases
The role of ion channel mutations in disease extends beyond rare monogenic diseases. Polymorphisms in ion channel genes have been implicated in susceptibility to several common diseases, including schizophrenia (Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium 2011), common forms of epilepsy (International League Against Epilepsy Consortium on Complex Epilepsies 2014), atrial fibrillation (Ellinor et al., 2012) , and diabetes (Reis et al., 2000; Hansen et al., 2005) . Genome wide association studies (GWAS) are powered to identify relatively common variants (typically found in 5% of the population) that have a moderate impact on disease susceptibility across the population as a whole. Very large sample sizes are needed to detect variants with genome-wide significance, and many relevant genetic contributes to common disease are likely to be missed by current GWAS approaches thanks to said variants being too rare, or too small in effect size. Furthermore, variant signals picked up by GWAS may not necessarily be causative per se since all inherited variants in a population segregate to some extent with other variants in nearby genes, a phenomenon known as linkage disequilibrium. Nonetheless it is worthy of note that genome wide significance has been reached for an SCN1A variant in a metaanalysis of epilepsy GWAS (total 8696 cases and 26,157 controls) (International League Against Epilepsy Consortium on Complex Epilepsies, 2014), for CACNA1C in a schizophrenia GWAS (8422 cases and 21,397 controls) (Schizophrenia Psychiatric GenomeWide Association Study (GWAS) Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium, 2011), and for both KCNN3 and HCN4 in atrial fibrillation (6707 cases and 52,426 controls) (Ellinor et al., 2012 ).
An alternative approach to GWAS that can be used to identify rarer variants that may play a role in common disease susceptibility is to compare the number of observed rare variants in any given gene between a disease population and a control population, a technique that is referred to as burden analysis. Ion channels that have been implicated in type 2 diabetes through this type of methodology have been KCNJ11 (Hansen et al., 2005) and ABCC8 (Reis et al., 2000) . With regards to epilepsy, the Epi4K consortium and Epilepsy Phenome/Genome project expanded this methodology to compare the exomes of 1185 individuals with familial epilepsies with 3877 control subjects. In the epilepsy group there were significantly higher proportions of ultrarare variants in a number of ion channel genes, including GABRG2, SCN1A, ATP1A3, KCNQ2, CACNA1B, and GRIN2A (Epi4K consortium, Epilepsy Phenome/ Genome Project 2017). The authors concluded "that genes established as responsible for familial and rare severe epilepsies are also associated with common epilepsies." Atrial fibrillation and epilepsy are examples of common diseases that appear to have both single gene causes and polygenic causes, and yet the very same genes have been implicated in both types of causation. Because these are such commonly observed phenotypes, disentangling the relative contribution of any given gene remains an enormous challenge, if not an impossibility. The genetic aetiology of these conditions is therefore perhaps best conceptualised as part of a spectrum, as illustrated in Fig. 2. 
The quest for modifying genes
In all but the most severe and highly penetrant single gene channelopathies, genetic modifiers are presumed to exist, since phenotypic variability is observed among those harbouring identical genetic mutations. For example, in affected members of families with genetic epilepsy with febrile seizures plus (GEFSþ) due to mutations in SCN1A, there are some individuals with a markedly more severe phenotype (Escayg et al., 2000a,b) . The same phenomenon is observed in GEFS þ families with GABRG2 mutations (Harkin et al., 2002) , and in families with KCNQ2 mutations, the majority of whom have self-limiting neonatal seizures, but some of whom continue to have epileptic seizures into childhood and adulthood (Singh et al., 2003) . Whilst SCN1A truncations are generally found in association with more severe phenotypes, and in patients who experience a seizure-worsening when the antiepileptic drug Carbamazepine is used, there are isolated case reports of patients with SCN1A truncations who have mild phenotypes and Carbamazepine-responsiveness (Takaori et al., 2017) . In some channelopathies entirely different phenotypes can be seen in association with an identical mutation. For example in a family in which the mother and son shared the same missense mutation in ABCC8 the son presented with congenital hyperinsulinism, whilst the mother had a focal epilepsy but demonstrated completely normal regulation of insulin secretion (Stranks et al., 2016) . The concept of genetic modifiers is most compelling in the monogenic forms of epilepsy, autism, and cardiac arrhythmias e conditions where complex polygenic aetiology is already presumed to exist for the majority of cases, and the role of common, low-effect variants is already established (Speed et al., 2014) . However, the challenge of identifying genetic modifiers is huge. GWAS requires large sample numbers to identify genomic signals of disease association, so to apply this same methodology to approach the identification of genetic modifiers in a small number of cases where a rare monogenic cause has been identified is an impossibility.
Mouse models of sodium channel related epilepsy have however made some headway in identifying candidate disease modifying genes thanks to the initially serendipitous discovery that SCN2A mutants demonstrate a strain-dependant phenotype. Hawkins et al. found that in the SCN2A Q54 (mice carrying the gain-offunction mutation GAL879-881QQQ) model of epilepsy [B6XSJL/J] F1 mice demonstrated a more severe phenotype than C57BL/6 J mice. They used mapping techniques to identify a possible modifying variant on the HLF (hepatic leukaemia factor) gene. They then crossed both SCN2A Q54 and SCN1A knockout mice with HLF knockout mice and demonstrated that in both SCN1A and SCN2A models HLF deficiency was associated with a more severe phenotype. Because HLF haploinsufficiency is believed to result in downregulation of the pyridoxal kinase enzyme which converts pyridoxine to pyridoxal 5' phosphate, they gave the SCN2A Q54 mice a pyridoxine restricted diet and demonstrated a worsening of seizures . Further work by this same group on mouse models has identified candidate genetic modifiers of sodium channel epilepsy in other ion channel genes, including a GABRA2 variant in an SCN1A knockout model, which was partially rescued by Clobazam , and a CACNA1G variant in the SCN2A Q54 mutant model (Calhoun et al., 2016) .
In a parallel story, mouse models have been used to investigate for genetic modifiers of cardiac channelopathies. Remme et al. demonstrated that in an SCN5A 1798insD/þ model, 129P2 mice demonstrated a more severe phenotype than FVB/N mice. They used pan-genomic mRNA expression techniques to uncover a dramatic reduction in SCN4B mRNA in the more severely affected strain (Remme et al., 2009 ). In humans, evidence for genetic modifiers of channelopathies is largely limited to isolated case reports of patients with pathogenic or possible pathogenic mutations identified in additional genes to the primary ion channel e often referred to as "blended phenotypes." Examples of such blended phenotypes include: a family with SCN5A-related cardiac conduction disorder in which the presence of a p.Lys897Thr variant in HERG2 segregated with those members of the family who had a more severe phenotype (Jagodzinska et al., 2016) ; an individual with a very severe progressive cardiac conduction disorder who was found to have predicated damaging mutations in both KCNK17 and SCN5A (Friedrich et al., 2014) ; and 2 siblings who had basal ganglia calcifications and generalised epilepsy who were found to have heterozygous damaging mutations in both CHRNB2 (known to be associated with familial epilepsy) and SLC20A2 (known to cause primary familial basal ganglia calcification) (Fjaer et al., 2015) . There is also increasing evidence that common polymorphisms elsewhere in the same ion channel gene that is believed to be causative of the disease may influence phenotype. This phenomenon has been reported for the c.1059G > A polymorphism in KCNQ1 which has been associated with further prolongation of the QT interval in patients with long QT syndrome due to pathogenic KCNQ1 mutations (Kapplinger et al., 2017) , and with the SCN4A p.Ser906Thr polymorphism which appears to exacerbate the phenotype of patients with hyperkalaemic periodic paralysis caused by p.Iso693Thr mutations in the same gene (Fan et al. 2016) .
It is of course equally possible that some genetic variants confer relative protection from channelopathy-related disease, but these are likely to be even harder to identify than deleterious genetic modifiers. In a mouse model of SCN1A-related Dravet syndrome, knockout of both Tau alleles resulted in a milder phenotype with reduced epileptic spikes on EEG, and improved learning, memory and executive function (Gheyara et al., 2014) . Similarly, knockout of SCN2A has been demonstrated to improve survival in a KCNA1-null mouse model of SUDEP (Mishra et al., 2017) .
Precision medicine
The ion channel-related epilepsies are an area of medicine where precision therapy has shown early promise. The idea that dysfunctional channels can be targeted with drugs acting on them is a highly attractive one, particularly as this has emerged as a possibility in an area of medicine where treatment resistance is common (Berg et al., 2009; Cockerell et al., 1995) , and evidence based therapy is lacking (Marson et al., 2007a (Marson et al., , 2007b . Intuitively it is easier to use drugs to block the action of an overactive ion channel than to open up an underactive one, and this has proven to be the case, with the majority of precision medicine successes reported so far being in cases where there is a gain-of-function channelopathy. Due to the extreme rarity of these cases, all evidence base is restricted to anecdotes. Nonetheless these at least provide a proof-of-principle for precision medicine in channelopathies.
Current approaches to precision-medicine begin with identification of the genetic cause of a disease and thereafter take two broad forms: i) rational choice of existing therapies based on established evidence or known mechanisms of action; ii) systematic screening for novel or repurposed drugs using models that incorporate the mutation or genetic mechanism. In future is it possible that precision medicine may not need, nor indeed benefit, from exact knowledge of genetic causation. If high throughput induced progenitor stem cell (iPSC) models can be developed for drug screening, then it may be possible to identify the optimum medication for an individual's disease based on a model that takes into account the full genomic background of an individual, including disease modifying genes (Avior et al., 2016) , though such models would fail to account for the tissue-specific effects of somatic mutations. Another future avenue for precision medicine is the development of non-genomic biomarkers that predict treatment response, such as metabolomic profiles, or functional and spectroscopic imaging (Al Zwieri et al, 2010) .
Rational therapy choice based on established evidence/known mechanisms of action
This type of precision medicine is already common practice in some childhood-onset epilepsies. When a patient is found to have an SCN1A mutation, most clinicians will withdraw, or avoid using, any sodium channel blocking medications, based on anecdotal reports of seizure-worsening (Brunklaus et al., 2013) . This approach can be rationalised by the knowledge that these mutations cause loss-of-function and that Na v 1.1 is preferentially expressed in inhibitory interneurons (Ogiwara et al., 2007) . Therefore further reducing the excitability of these inhibitory neurones through sodium channel blockade would be expected to promote overall neuronal excitability. Loss-of-function mutations in KCNQ2 can cause self-limiting familial neonatal seizures as well as a more severe phenotype of early-onset developmental and epileptic encephalopathy. In KCNQ2 anecdotal evidence supports the use of sodium channel blocking drugs (Pisano et al., 2015) . This can be rationalised on the basis that most KCNQ2 mutations are loss-offunction, and that K v 7.2 is preferentially expressed in excitatory hippocampal neurones. Loss of K v 7.2 function results in an increased intracellular K þ concentration. If the resulting reduction in polarisation of the neuronal cell membrane is counteracted by blocking the inwards movement of sodium ions, the increased excitability may be balanced out. Other examples of how the scientific understanding of the action of an ion channel has helped to guide drug choice are the use of Mexilitine in SCN2A-related epilepsy (Foster et al., 2016) , Retigabine (a potassium channel opener) for KCNQ2/KCNQ3-related epilepsies , and sulphonylureas in neurodevelopmental disorders related to KCNJ11 mutations (Slingerland et al., 2008) . In long QT syndrome, beta blockers are thought to be the most rational treatment choice for patients with KCNQ1 mutations (Barsheshet et al., 2012) , whilst medications that preferentially act on the fast inactivation type of sodium channel, are believed to be most effective for those with SCN5A Priori et al., 2000) .
Using in vitro and in vivo models to screen for effective drugs
This can be done on a small scale using individual patient genotypes to test a limited number of rationally chosen drugs, or on large scale using high throughput models of genetic channelopathy to test a large number of drugs. The main reported successes of the former approach are with epilepsies due to gain-of-function mutations in KCNT1, GRIN2A, GRIN2D, and SCN8A.
Following anecdotal reports of treatment success of quinidine in KCNT1-related severe epilepsies (Bearden et al., 2014) , Mikati et al. demonstrated in vitro that quinidine inhibited hKCNT1 currents in a Xenopus oocyte model. The oocytes expressed the mutations found in two patients with epilepsy of infancy with migrating focal seizures (EIMFS) due to de novo KCNT1 mutations. Both patients were subsequently treated with quinidine, but only one had a clinically detectable reduction in seizures (Mikati et al., 2015) . The reason for these discordant clinical responses to quinidine despite similar in vitro evidence for efficacy is unclear, and highlights the need to consider the functional impact of mutations within a more systems-wide context.
Almost identical approaches, involving in vitro testing of drugs in Xenopus oocytes or human dorsal root ganglion cells expressing the mutations found in real patients, prior to a trial of medication, have been used successfully in GRIN2A (Memantine) (Pierson et al., 2014) , GRIN2D (Memantine and Magnesium sulphate) (Li D. et al., 2016) , SCN8A (Phenytoin) (Barker et al., 2016) , SCN4A (Desaphy et al., 2016) , and SCN9A (Carbamazepine) (Geha et al., 2016) .
Whilst these small scale and highly personalized approaches have clearly delivered results to the patients concerned, scaling them up remains a challenge, and the number of drugs that has been tested for in vitro effect in each case has been limited. Conversely, high throughput screening of medications for efficacy in specific genetic channeloapthies using iPSC (Avior et al., 2016) and in vivo whole organism models has facilitated the identification of new and repurposed medications. For example, through in vivo modelling in zebrafish identified Clemizole (an antihistamine) as a potential treatment for SCN1A-related epilepsy (Baraban et al., 2013) . Whilst whole organism models have the advantage of more accurately reflecting complete neuronal circuitry, they are more expensive to produce, and are not specific for an individual genetic variant.
SCN1A as an example of the challenges facing precision medicine
Whilst in Dravet syndrome knowledge of the SCN1A mutation does appear to provide clinicians with immediately tangible information to guide treatment choice, (Brunklaus et al., 2013) , in reality the relationship between genotype and treatment response is likely to be highly complex. There are reports of patients who in fact benefit from sodium channel blocking medications, and who experience a deterioration when these medications are withdrawn (Takaori et al., 2017; Dalic et al., 2015) . To some extent, variations in medication response may be explained by the location and functional effect of the SCN1A mutation. There is some suggestion that those patients with SCN1A truncation mutations are more likely to respond to Stiripentol and Topiramate, whilst those with missense mutations are more likely to respond to Clonazepam and Triple Bromide. However these data come from retrospective reports from clinicians and must be viewed with caution (Ishii et al., 2016) . As discussed above, dividing mutations into truncating and nontruncating oversimplifies the functional consequences of genetic variants. To truly understand medication response in SCN1A-related epilepsy a more complete analysis of the functional effects of specific missense mutations is required, as well as a consideration of the influence of Na v 1.1 channel expression and distribution within neuronal networks (which is likely to vary between individuals), and the role of other genetic modifiers.
Many other genetic factors are likely to have an impact on treatment response, besides the particularities of the ion channel mutation. These include: predisposition to specific adverse drug reactions, which is often related to HLA type (Amstutz et al., 2014) ; genetic variants that affect drug absorption, distribution, metabolism, and elimination (Chen et al., 2014; Shaheen et al., 2014; L€ oscher et al., 2009; Saygi et al., 2014) ; and genetic variation at the site of drug targets, which in the case of channelopathy treatment, are often in fact ion channels themselves (Thompson et al., 2011) . It is important to bear all of these in mind where precision medicine is an objective.
Conclusion
We have now entered a very exciting era of genomic medicine, in which obtaining whole genome information on individuals is rapidly becoming the most cost effective way to diagnose rare genetic disease. As the use of Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) becomes more widespread it is almost certain that new ion channel genes will be linked to both monogenic and complex genetic diseases, and that new genotypephenotype relationships will emerge. Large scale analysis of whole genome data will also provide the opportunity to identify relevant genetic modifiers in "monogenic" channelopathies, some of which may have significant implications for treatment. The emergence of such genetic modifiers will lead to a fundamental reconceptualization of monogenic and complex genetic diseases as existing on a continuous spectrum. The genetic channelopathies are an area where precision medicine has shown early promise, though as yet no model that accurately expresses both genetic modifiers and systems wide context has been developed. To permit widespread application of precision techniques current technical and financial barriers will need to be overcome.
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